Gene and cell therapy funding opportunities in horizon 2020: an overview for 2014-2015.
作者信息
Gancberg David, Draghia-Akli Ruxandra
机构信息
Directorate Health, Directorate-General for Research and Innovation, European Commission, Brussels B-1049, Belgium .
出版信息
Hum Gene Ther. 2014 Mar;25(3):175-7. doi: 10.1089/hum.2014.017. Epub 2014 Feb 21.
Abstract
摘要
相似文献
1
Gene and cell therapy funding opportunities in horizon 2020: an overview for 2014-2015.
Hum Gene Ther. 2014 Mar;25(3):175-7. doi: 10.1089/hum.2014.017. Epub 2014 Feb 21.
2
European Society of Gene and Cell Therapy (ESGCT) at 25: A Gene Therapy Community at Its Prime and on the Move.
Hum Gene Ther. 2017 Nov;28(11):940. doi: 10.1089/hum.2017.29049.trf.
3
Celebrating 25 Years of the European Society of Gene and Cell Therapy.
Hum Gene Ther. 2017 Nov;28(11):939. doi: 10.1089/hum.2017.29054.rra.
4
A historical view on the creation of the European society for cell and gene therapy.
Hum Gene Ther. 2013 Jan;24(1):4-11. doi: 10.1089/hum.2012.2524.
5
European Society for Gene and Cell Therapy-Inaugural Learned Society in the Field Worldwide: A Vision on Its Birth, Life, and Prospects for Sustainability.
Hum Gene Ther. 2017 Nov;28(11):941-950. doi: 10.1089/hum.2017.177.
6
A decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: An evaluation of regulatory decision-making.
Cytotherapy. 2018 Jun;20(6):769-778. doi: 10.1016/j.jcyt.2018.03.038. Epub 2018 May 2.
7
The business case for cell and gene therapies.
Nat Biotechnol. 2014 Dec;32(12):1192-3. doi: 10.1038/nbt.3084.
8
1Q21-thirst for preclinical biotechs unquenched.
Nat Biotechnol. 2021 May;39(5):538-539. doi: 10.1038/s41587-021-00918-3.
9
Gene and Cell Therapy: Success Stories and Future Challenges.
Mol Ther. 2019 May 8;27(5):891-892. doi: 10.1016/j.ymthe.2019.04.012. Epub 2019 Apr 19.
10
Value-based payment and financing for cell and gene therapies: challenges and potential solutions.
J Med Econ. 2024 Jan-Dec;27(1):678-681. doi: 10.1080/13696998.2024.2346406. Epub 2024 Apr 27.
引用本文的文献
1
Orchestrating an immune response against cancer with engineered immune cells expressing αβTCRs, CARs, and innate immune receptors: an immunological and regulatory challenge.
Cancer Immunol Immunother. 2015 Jul;64(7):893-902. doi: 10.1007/s00262-015-1710-8. Epub 2015 May 20.
Zotero 插件